Recent experiments suggest the presence of two types of sigma """"""""opiate"""""""" binding sites, a phencyclidine-sensitive site (sigma p) and a haloperidol-sensitive site (sigma H). The sigma h site has a unique distribution in the brain and is especially concentrated in many brain regions associated with movement and posture. Of these, the red nucleus, a sizeable nucleus in the midbrain tegmentum, is of special interest because it is rich in sigma h receptors but largely lacking in other known receptor types. It is possible that the sigma h site underlies the effects of various psychotomimetic opioids. However, binding experiments that demonstrated the existence of sigma h sites do not assure that the entity is a functional receptor. Therefore, the proposed research aims to establish its functional significance. Early studies employ binding techniques to verify the specificity of two apparently selective sigma h ligands, di-o-tolyl-guanidine (DTG) and (+)- pentazocine. Then, in vivo approaches are used to address the functional significance of the sigma h binding site. The proposed studies use microinjection/behavior and microiontophoresis/unit- recording approaches focusing on the red nucleus to avoid, to the greatest possible extent, interactions of the ligands with unwanted receptor types. In these experiments the structure- activity relationships will be examined as will interactions between various sigma h ligands. In addition, chronic administration of sigma h ligands will be used in attempts to up- or down- regulate the sigma h receptor. If the sigma h binding site is a functioning biological receptor it should be possible to regulate its expression, and the efficacy of sigma h ligands should be affected concomitantly. In addition, a correlation between the binding affinity of various ligands and their in vivo potency would suggest biological significance. Finally, antagonism between certain pairs of ligands would also suggest biological significance. The proposed studies should, therefore, provide several bases for judging the functional relevance of the sigma h receptor and lay a foundation for future investigations of the mechanism of action of the sigma h ligands.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA004988-01
Application #
3210885
Study Section
(SRCD)
Project Start
1988-09-30
Project End
1991-08-31
Budget Start
1988-09-30
Budget End
1989-08-31
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Brown University
Department
Type
Schools of Arts and Sciences
DUNS #
001785542
City
Providence
State
RI
Country
United States
Zip Code
02912
Sanudo-Pena, M C; Tsou, K; Delay, E R et al. (1997) Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223:125-8
Matsumoto, R R; Bowen, W D; Walker, J M et al. (1996) Dissociation of the motor effects of (+)-pentazocine from binding to sigma 1 sites. Eur J Pharmacol 301:31-40
Weiser, S D; Patrick, S L; Mascarella, S W et al. (1995) Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of sigma receptor ligands. Eur J Pharmacol 275:1-7
Martin, W J; De Costa, B R; Walker, J M (1994) Effects of sigma ligands on rat cerebellar Purkinje neuron firing: an iontophoretic study. Brain Res Bull 35:303-9
Leitner, M L; Hohmann, A G; Patrick, S L et al. (1994) Regional variation in the ratio of sigma 1 to sigma 2 binding in rat brain. Eur J Pharmacol 259:65-9
Bowen, W D; Tolentino, P J; Kirschner, B N et al. (1993) Sigma receptors and signal transduction: negative modulation of signaling through phosphoinositide-linked receptor systems. NIDA Res Monogr 133:69-93
Walker, J M; Bowen, W D; Patrick, S L et al. (1993) A comparison of (-)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests role of sigma 2 receptors in motor function. Eur J Pharmacol 231:61-8
Hemstreet, M K; Matsumoto, R R; Bowen, W D et al. (1993) Sigma binding parameters in developing rats predict behavioral efficacy of a sigma ligand. Brain Res 627:291-8
Patrick, S L; Walker, J M; Perkel, J M et al. (1993) Increases in rat striatal extracellular dopamine and vacuous chewing produced by two sigma receptor ligands. Eur J Pharmacol 231:243-9
Bowen, W D; Walker, J M; de Costa, B R et al. (1992) Characterization of the enantiomers of cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)cyclohexylamine (BD737 and BD738): novel compounds with high affinity, selectivity and biological efficacy at sigma receptors. J Pharmacol Exp Ther 262:32-40

Showing the most recent 10 out of 21 publications